Subject 2 experienced graft failure 4 months and 7 days after conversion to abatacept - Small Molecule Inhibitors of KDM5 Therapeutic Strategies in Human Breast Cancer
Subject 2 experienced graft failure 4 months and 7 days after conversion to abatacept - Small Molecule Inhibitors of KDM5 Therapeutic Strategies in Human Breast Cancer Skip to content Subject 2 experienced graft failure 4 months and 7 days after conversion to abatacept. hypertransaminasemia.